Retrospective cohort study of the predictors of weight loss after 3 months of treatment with Liraglutide for patients with obesity/overweight at the “Centre d’Obésité et de Contrôle du Poids” (COCP)

Abstract

Abstract Objective:Different responses were observed in patients on Liraglutide therapy, where data showed more significant weight loss in some people compared to others. The aim of this study was to assess the percentage of weight loss and to determine possible weight loss predictors in Lebanese patients with obesity/overweight who were treated with Liraglutide. Methods: This was a retrospective cohort study involving patients with obesity/overweight from the Middle East Institute of Health (MEIH) in Lebanon. Patient charts were reviewed between 2014 and 2018. A total of 100 patients fulfilled the criteria and were followed up for 3 months. Measures collected were weight and waist circumference at baseline, after 1 and after 3 months of therapy, age, gender, BMI, metformin use and presence of diabetes, hypertension or dyslipidemia. Results: A significant weight loss of 5.79 kg and decrease in waist circumference of 7.53 cm was found after 3-months follow up. None of the chosen predictors (age, gender, cumulative liraglutide dose, weight loss after 1-month, diabetes, hypertension, dyslipidemia, HOMA-IR and concomitant Metformin treatment) could significantly predict the response to therapy. Conclusion:Our results confirm the efficacy of Liraglutide in people with obesity/overweight in Lebanon. None of the chosen predictors seems to predict the long-term efficacy of the drug in order to identify patients who will benefit from treatment continuation.